Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 4/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.43 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250927 | 0.92 | ADRA1A (0.54) | ADRA1AADRA2AADRA1DADRA1BCYP2D6 | |
| SCHEMBL8865200 | 0.81 | ESR1 (0.44) | ADRA1AADRA2AADRA1DADRA1B | |
| SCHEMBL8865718 | 0.81 | SRD5A1 (0.39) | ADRA1AADRA2AADRA1DADRA1BCYP2D6 | |
| SCHEMBL8865117 | 0.81 | SRD5A1 (0.39) | ADRA1AADRA2AADRA1DADRA1BCYP2D6 | |
| SCHEMBL8865796 | 0.80 | ADRA2A (0.49) | ADRA1AADRA2AADRA1DADRA1BADRA2B | |
| SCHEMBL8865410 | 0.79 | ADRA2A (0.59) | ADRA2ACYP2D6 | |
| SCHEMBL8866491 | 0.79 | P2RX7 (0.38) | ADRA1AADRA2AADRA1DADRA1BHTR1A | |
| SCHEMBL7103607 | 0.79 | ADRA2A (0.59) | ADRA1AADRA2AADRA1DADRA1BCYP2D6 | |
| SCHEMBL7608212 | 0.79 | ADRA2A (0.40) | ADRA1AADRA2AADRA1DADRA1BOPRM1 | |
| SCHEMBL8865654 | 0.79 | SLC6A2 (0.35) | ADRA1AADRA2AADRA1DADRA1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | claimed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | claimed |
| US-5658938-A | HYPOTENSIVE AGENT, ANTIISCHMIC AGENTS | U C B S.A. (BE) | 1997-08-19 | — | — | US | claimed |
| EP-0717037-A1 | Substituted 1H-imidazoles having alpha 2-agonistic and alpha 1-antagonistic activity | U C B, S.A. (BE) | 1996-06-19 | — | — | EP | claimed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-0888309-B1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | ORION CORP (FI) | 2003-03-19 | — | — | EP | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| US-6479530-B2 | SUBSTITUTED 4(5)-(1-INDANYL,-INDANYLMETHYL, INDANYLMETHYLEN), 4(5)-(1-(1,2,3,4-TETRAHYDRONAPHTHYL, -NAPHTHYLMETHYL AND NAPHTHYLMETHYLEN)IMIDAZOLES; HYPOTENSIVE, ISCHEMIC AND ANXIOLYTIC AGENTS; NERVOUS AND MUSCULAR SYSTEM DISORDERS | ORION CORPORATION (FI) | 2002-11-12 | — | — | US | disclosed |
| EP-0888309-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | ORION CORPORATION (FI) | 1999-01-07 | — | — | EP | disclosed |
| US-5658938-A | HYPOTENSIVE AGENT, ANTIISCHMIC AGENTS | U C B S.A. (BE) | 1997-08-19 | — | — | US | disclosed |
| US-5658938-A | HYPOTENSIVE AGENT, ANTIISCHMIC AGENTS | U C B S.A. (BE) | 1997-08-19 | — | — | US | disclosed |
| WO-1997012874-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | Orion-Yhtymä Oy (FI) | 1997-04-10 | — | — | WO | disclosed |
| CN-1133837-A | Substituted 1H-imidazoles | UCB SA (BE) | 1996-10-23 | — | — | CN | disclosed |
| EP-0717037-A1 | Substituted 1H-imidazoles having alpha 2-agonistic and alpha 1-antagonistic activity | U C B, S.A. (BE) | 1996-06-19 | — | — | EP | disclosed |
| EP-0717037-A1 | Substituted 1H-imidazoles having alpha 2-agonistic and alpha 1-antagonistic activity | U C B, S.A. (BE) | 1996-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | ADRA1A 188/4885ADRA2A 102/4885ADRA1D 66/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | ADRA1A 203/4885ADRA2A 106/4885ADRA1D 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.